VRX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Valeant Pharmaceuticals International Inc's revenue for the three months ended in Sep. 2014 was $2,056 Mil. Its revenue for the trailing twelve months (TTM) ended in Sep. 2014 was $8,047 Mil. Valeant Pharmaceuticals International Inc's revenue per share for the three months ended in Sep. 2014 was $6.02. Its revenue per share for the trailing twelve months (TTM) ended in Sep. 2014 was $23.80.
During the past 12 months, the average Revenue per Share Growth Rate of Valeant Pharmaceuticals International Inc was 73.60% per year. During the past 3 years, the average Revenue per Share Growth Rate was 46.50% per year. During the past 5 years, the average Revenue per Share Growth Rate was 36.70% per year. During the past 10 years, the average Revenue per Share Growth Rate was 8.50% per year.
During the past 13 years, Valeant Pharmaceuticals International Inc's highest 3-Year average Revenue per Share Growth Rate was 82.10% per year. The lowest was -10.80% per year. And the median was 15.80% per year.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Valeant Pharmaceuticals International Inc Revenue for the trailing twelve months (TTM) ended in Sep. 2014 was 2063.805 (Dec. 2013 ) + 1886.2 (Mar. 2014 ) + 2041.1 (Jun. 2014 ) + 2056.2 (Sep. 2014 ) = $8,047 Mil.
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Valeant Pharmaceuticals International Inc Annual Data
Valeant Pharmaceuticals International Inc Quarterly Data
Disclaimers: GuruFocus.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The gurus may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.